drugset / Trial / NCT03983668
CMP-001 for Relapsed and Refractory Lymphoma
Phase 1/2
Terminated
14 enrolled
Umar Farooq
Checkmate Pharmaceuticals · collabMerck Sharp & Dohme LLC · collabUniversity of Iowa · collab
NaSequentialOpen-labelTreatment
Summary
This study is a single-arm, open-label, phase I/II trial designed to find a CMP-001 dose that, in combination with pembrolizumab, has optimal clinical efficacy and acceptable toxicity for patients with relapsed and refractory lymphomas.
Timeline
- Start
- 2020-01-31
- Primary completion
- 2024-08-23
- Completion
- 2025-04-08
Publications
- Background Thall PF, Cook JD. Dose-finding based on efficacy-toxicity trade-offs. Biometrics. 2004 Sep;60(3):684-93. doi: 10.1111/j.0006-341X.2004.00218.x.
- Background Thall PF, Herrick RC, Nguyen HQ, Venier JJ, Norris JC. Effective sample size for computing prior hyperparameters in Bayesian phase I-II dose-finding. Clin Trials. 2014 Dec;11(6):657-66. doi: 10.1177/1740774514547397. Epub 2014 Sep 1.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vidutolimod | Other / unclassified | 5 mg | Other |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |